Pronulife® FitStay

• Obesity, recognized as a chronic disease by WHO and the European Commission, poses a significant global health issue.
• By 2035, it is estimated that 1.9 billion people worldwide will be obese, with 1 in 4 individuals affected.
• In Taiwan, the overweight and obesity rate among adults has been on the rise, reaching 50.3%.
• Obesity is closely linked to various diseases, including type 2 diabetes, cardiovascular diseases, cancer, and more.
• Defining Obesity: WHO uses BMI (Body Mass Index) to measure obesity, with a BMI of 24 or higher considered obese.
• Microbiota-Gut-Brain Axis: Gut microbiota composition impacts the host's physical and psychological well-being, influenced by long-term dietary habits.
• High-fat and high-sugar foods can trigger inflammation through the microbiota-gut-brain axis, affecting brain function.
• Studies on mice showed changes in gut bacteria abundance when fed a high-fat diet, impacting neurotransmitter production with physiological effects on the host.

• Better efficacy
• Stronger immunity
• Shorter recovery time
• Function: Weight management

• Our R&D Center has selected PRONULIFE® FitStay probiotics: Bifidobacterium animalis subsp. infantis CP-9 and Lactobacillus rhamnosus bv-77.
• This formula reduces intestinal fat absorption, slows weight gain, and decreases heart fat accumulation. It addresses fatty liver and kidney function issues in obesity.
• Human experiments show it lowers body weight, blood lipid levels, and other obesity-related values.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.